Market Pulse
Daily · Sep 17, 2026 · data.go.kr + ECOS
KOSPI
6,715.41
-2.56 (-0.04%)
KOSDAQ
822.18
+6.20 (+0.76%)
KOSPI 200
1,058.27
-1.78 (-0.17%)
USD/KRW
1,382.20
009420KOSPI·Mar 21, 2025
Batoclimab phase 3 trial data announced
Mirae Asset Securities published a company analysis report on HANALL BIOPHARMA CO. Co., Ltd. (009420) titled "Batoclimab phase 3 trial data announced".
Summary
Covers HANALL BIOPHARMA CO. Co., Ltd. (009420).
Covered stock
More on 009420
Imeroprubart��s best-in-class potential remains intactMirae Asset Securities · May 21, 2026IMVT-1402 to regain focus from 2H26Mirae Asset Securities · Mar 13, 2026Promising batoclimab results heighten expectations for IMVT-1402Mirae Asset Securities · Sep 25, 20251Q25 to be a key inflection pointMirae Asset Securities · Feb 27, 2025